A new era for rheumatoid arthritis is beginning to unfold, leading the charge is several new drugs which are giving arthritis sufferers new options that many have never enjoyed. A new study released Tuesday, three new drugs; rituximab, abatacept and tocilizumab are on the cutting edge of science. Rheumatoid arthritis is a chronic inflammatory joint disease that attacks the joints, producing harsh pain, stiffness and swelling. Rituximab and abatacept have already received approval to treat of patients who suffer from this painful illness. Tocilizumab is still in phase III clinical trials testing. According to HealthDay, Traditional treatments for rheumatoid arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and disease-modifying anti-rhe View the rest of this article
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment